Pacific Biosciences of California Inc 2026年季度报告

Form 10-Q_____________________________________________________________________________________________ (Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-34899 Pacific Biosciences of California, Inc.(Exact name of registrant as specified in its charter)_____________________________________________________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo Number of shares outstanding of the issuer’s common stock as of April30, 2026: 310,601,688. TABLE OF CONTENTS Item 1. Financial Statements (unaudited):Condensed Consolidated Balance Sheets as of March 31, 2026and December 31, 20253Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months EndedMarch 31, 2026 and 20254Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026and 20255Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20256Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations26Item 3. Quantitative and Qualitative Disclosures About Market Risk36Item 4. Controls and Procedures36PART II. OTHER INFORMATIONItem 1. Legal Proceedings37Item 1A. Risk Factors39Item 2. Unregistered Sales of Equity Securities and Use of Proceeds80Item 3. Defaults Upon Senior Securities80Item 4. Mine Safety Disclosures80Item 5. Other Information81Item 6. Exhibits82Signatures83 PART I. FINANCIAL INFORMATION See accompanyingnotesto the condensed consolidated financial statements. Balance at December 31, 2025Net lossOther comprehensive lossIssuance of common stock in conjunctionwith equity plansShare-based compensation expenseBalance at March 31, 2026 (In thousands)Balance at December 31, 2024Net lossOther comprehensive lossIssuance of common stock in conjunctionwith equity plansShare-based compensation expenseBalance at March 31, 2025 See accompanyingnotesto the condensed consolidated financial statements. Table of Contents PACIFIC BIOSCIENCES OF CALIFORNIA, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enablescientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complexproblems. Our products and technology, which primarily consist of our HiFi long-read sequencing systems, address a broad set ofapplications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, andother emerging applications. Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most completeand accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genomecenters, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceuticalcompanies, and agricultural companies. References in this report to “PacBio,” “we,” “us,” the “Company,” and “our” refer to Pacific Biosciences